Chemoradiation followed by adjuvant durvalumab in stage III non–small cell lung cancer: Real‐world comparison of treatment outcomes to historical controls treated with chemoradiation alone

Abstract Objective Compare outcomes in patients with stage III non–small cell lung cancer (NSCLC) treated with chemoradiation and adjuvant durvalumab to historical controls treated with chemoradiation alone. Methods The records of patients with stage III NSCLC treated with definitive chemoradiation...

Descrición completa

Detalles Bibliográficos

Principais autores:	Akram Saad, Jeffrey Goldstein, Sarit Appel, Sameh Daher, Damien Urban, Amir Onn, Hadas Gantz‐Sorotsky, Anastasiya Lobachov, Teodor Gottfried, Benjamin Spieler, Jair Bar
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2022-06-01
Series:	Thoracic Cancer
Assuntos:	durvalumab immunotherapy non–small cell lung cancer PD‐L1 stage III
Acceso en liña:	https://doi.org/10.1111/1759-7714.14452
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!